Literature DB >> 20652362

Determination of the methylation status of MGMT in different regions within glioblastoma multiforme.

Mark G Hamilton1, Gloria Roldán, Anthony Magliocco, John B McIntyre, Ian Parney, Jacob C Easaw.   

Abstract

Epigenetic silencing of the MGMT gene through promoter methylation correlates with improved survival in Glioblastoma Multiforme (GBM) patients receiving concurrent chemoradiotherapy. Although the clinical benefit is primarily seen in patients with methylated MGMT promoter, some unmethylated patients also respond to Temozolomide. One possible explanation may be intratumoral heterogeneity. This study was designed to assess the methylation status of the MGMT promoter in different areas of GBM and determine if methylation status varied depending on the fixation technique (paraffin-embedding versus fresh frozen) used to store tissue. Using intraoperative navigation, biopsies were obtained from three distinct regions: the enhancing outer area, the non-enhancing inner core, and an area immediately outside the enhancing region. Only patients with GBM were included for evaluation and analysis. Samples taken from each area were divided with half stored by flash freezing and the other half stored using paraffin fixation. Methylation Specific-PCR (MS-PCR) was used for analysis of MGMT promoter methylation. Thirteen patients were included. Ten were male with a median age of 62 years. In each patient, samples were taken from the enhancing rim and the necrotic centre. However, it was not considered safe or feasible to obtain samples from the area immediately adjacent to the enhancing tumor rim in one case. All patients were homogeneous for methylation status throughout their tumor and tissue taken adjacent to it when frozen tissue was used. However, four patients had discrepancies in the MGMT promoter status between the frozen and paraffin-embedded blocks and one patient was not homogeneous within the tumor when paraffin-embedded tissue was used. MGMT promoter methylation status was homogeneous in all GBM tumors. Our observation that methylation status varied depending if the DNA was extracted from paraffin-embedded versus frozen tissue is concerning. Although the reason for this is unclear, we postulate that the timing from resection to fixation or the process of fixation itself may potentially alter methylation status in paraffin-embedded tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652362     DOI: 10.1007/s11060-010-0307-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

Review 1.  Effect of fixatives and tissue processing on the content and integrity of nucleic acids.

Authors:  Mythily Srinivasan; Daniel Sedmak; Scott Jewell
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different methods.

Authors:  D Talaulikar; J X Gray; B Shadbolt; M McNiven; J E Dahlstrom
Journal:  J Clin Pathol       Date:  2007-06-01       Impact factor: 3.411

3.  Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.

Authors:  Wolfgang Wick; Antje Wick; Jörg B Schulz; Johannes Dichgans; Hans P Rodemann; Michael Weller
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

Review 4.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

Authors:  Michael Weller; Roger Stupp; Guido Reifenberger; Alba A Brandes; Martin J van den Bent; Wolfgang Wick; Monika E Hegi
Journal:  Nat Rev Neurol       Date:  2009-12-08       Impact factor: 42.937

5.  Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent.

Authors:  K Ochs; B Kaina
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

6.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Authors:  M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

7.  Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.

Authors:  Kazunari Yachi; Takao Watanabe; Takashi Ohta; Takao Fukushima; Atsuo Yoshino; Akiyoshi Ogino; Yoichi Katayama; Hiroki Nagase
Journal:  Int J Oncol       Date:  2008-09       Impact factor: 5.650

8.  Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.

Authors:  Jonathon F Parkinson; Helen R Wheeler; Adele Clarkson; Catriona A McKenzie; Michael T Biggs; Nicholas S Little; Raymond J Cook; Marinella Messina; Bruce G Robinson; Kerrie L McDonald
Journal:  J Neurooncol       Date:  2007-11-15       Impact factor: 4.130

9.  Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens.

Authors:  M Preusser; L Elezi; J A Hainfellner
Journal:  Clin Neuropathol       Date:  2008 Nov-Dec       Impact factor: 1.368

10.  Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

Authors:  Monika E Hegi; Annie-Claire Diserens; Sophie Godard; Pierre-Yves Dietrich; Luca Regli; Sandrine Ostermann; Philippe Otten; Guy Van Melle; Nicolas de Tribolet; Roger Stupp
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

View more
  25 in total

1.  MGMT promoter methylation in non-neoplastic brain.

Authors:  Chih-Yi Hsu; Hsiang-Ling Ho; Yi-Chun Chang-Chien; Yi-Wen Chang; Donald Ming-Tak Ho
Journal:  J Neurooncol       Date:  2014-11-13       Impact factor: 4.130

2.  Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.

Authors:  Hinke F van Thuijl; Tali Mazor; Brett E Johnson; Shaun D Fouse; Koki Aihara; Chibo Hong; Annika Malmström; Martin Hallbeck; Jan J Heimans; Jenneke J Kloezeman; Marie Stenmark-Askmalm; Martine L M Lamfers; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchell S Berger; Peter Söderkvist; Barry S Taylor; Annette M Molinaro; Pieter Wesseling; Jaap C Reijneveld; Susan M Chang; Bauke Ylstra; Joseph F Costello
Journal:  Acta Neuropathol       Date:  2015-02-28       Impact factor: 17.088

Review 3.  MGMT testing allows for personalised therapy in the temozolomide era.

Authors:  A Dullea; L Marignol
Journal:  Tumour Biol       Date:  2015-10-30

4.  Correlation of histomorphologic prognostic markers and proliferative index with loss of heterozygosity 1p/19q and MGMT status in diffusely infiltrating gliomas.

Authors:  Prabal Deb; N S Mani; S M Sudumbrekar; Nitin Taneja; Seema Patrikar
Journal:  Med J Armed Forces India       Date:  2012-12-01

5.  Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications.

Authors:  Alba A Brandes; Enrico Franceschi; Alexandro Paccapelo; Giovanni Tallini; Dario De Biase; Claudio Ghimenton; Daniela Danieli; Elena Zunarelli; Giovanni Lanza; Enrico Maria Silini; Carmelo Sturiale; Lorenzo Volpin; Franco Servadei; Andrea Talacchi; Antonio Fioravanti; Maria Pia Foschini; Stefania Bartolini; Annalisa Pession; Mario Ermani
Journal:  Oncologist       Date:  2017-03-08

6.  MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.

Authors:  Fateme Salehi; Bernd W Scheithauer; Johann M Kros; Queenie Lau; Michael Fealey; Dana Erickson; Kalman Kovacs; Eva Horvath; Ricardo V Lloyd
Journal:  J Neurooncol       Date:  2011-02-11       Impact factor: 4.130

7.  Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype.

Authors:  Shaun D Fouse; Jean L Nakamura; C David James; Susan Chang; Joseph F Costello
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

Review 8.  Immunotherapy for brain cancer: recent progress and future promise.

Authors:  Christopher M Jackson; Michael Lim; Charles G Drake
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

9.  Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.

Authors:  Andrea Romano; Luca Pasquini; Alberto Di Napoli; Francesca Tavanti; Alessandro Boellis; Maria Camilla Rossi Espagnet; Giuseppe Minniti; Alessandro Bozzao
Journal:  J Neurooncol       Date:  2018-05-02       Impact factor: 4.130

10.  Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma.

Authors:  Miguel Angel Tejada Neyra; Ulf Neuberger; Annekathrin Reinhardt; Gianluca Brugnara; David Bonekamp; Martin Sill; Antje Wick; David T W Jones; Alexander Radbruch; Andreas Unterberg; Jürgen Debus; Sabine Heiland; Heinz-Peter Schlemmer; Christel Herold-Mende; Stefan Pfister; Andreas von Deimling; Wolfgang Wick; David Capper; Martin Bendszus; Philipp Kickingereder
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.